The 3 big things in Spirit Tech this week

A new consciousness framework proposes the temporal windows that neurofeedback builders have been missing

Two weeks after Maël Donoso's "Human Brain Zero" paper named the minimum viable brain state for consciousness research, Alfredo López Parra published a complementary framework in Frontiers in Integrative Neuroscience. His Emergent Flow Theory identifies three temporal integration windows, from autonomic preparation (~800ms) through perceptual binding (~100-300ms) to phenomenological continuity (seconds to minutes), and links them through a single testable equation grounding consciousness in HRV coherence, neural integration, and consolidation time. For Spirit Tech companies building neurofeedback or biofield tools, the practical takeaway is specific: measure autonomic coherence and cortical complexity together, in time-locked windows, rather than treating them as separate signals. The paper also reframes the Libet "readiness potential" delay not as evidence against agency but as a necessary cost of multi-level temporal integration.

The Catholic Church coined a word for people using AI chatbots as ritual altars: technomancers

The US Conference of Catholic Bishops published a report this week on AI-enabled occult practices. Beatrice Ugolini, a University of Bologna lecturer on occult languages, described users who prompt chatbots to generate rituals, demonic seals, and occult texts, treating the systems as sacred objects. Some interpret AI hallucinations as supernatural communication: "For a computer scientist, it's an error. To an occultist, it becomes the moment the demon speaks." The signal for Spirit Tech: AI spiritual use has reached the threshold where legacy institutions feel compelled to name it, categorize it, and warn against it, the clearest marker yet that AI spiritual companions have crossed from novelty to cultural force.

Compass Pathways' COMP360 reached FDA NDA rolling submission, the highest regulatory threshold any psilocybin therapy has cleared

The FDA granted Compass Pathways rolling NDA submission for COMP360, its psilocybin therapy for treatment-resistant depression, based on Phase 3 data from 1,000+ participants. Rolling submission means the FDA considers the evidence strong enough to review sections as they arrive rather than waiting for the complete package. Compass also received a Commissioner's National Priority Voucher that could compress post-submission review to one to two months, and reported $466M in cash extending its runway into 2028. For Spirit Tech builders, the timeline matters: if COMP360 reaches approval in 2027, demand for technology-enabled preparation, integration, and clinical monitoring tools shifts from speculative to operational.

New from the Community

1. Quantum Canvas: The Digital Mirror For Your Psyche
2. Wellness Navigator: Your personalized path to holistic well-being
3. Consciousness Hub: Consciousness Education and Research Platform